Pub Date : 2022-10-14DOI: 10.1007/s40588-022-00182-2
E. Mahenthiralingam, R. Weiser, R. Floto, J. Davies, J. Fothergill
{"title":"Selection of Relevant Bacterial Strains for Novel Therapeutic Testing: a Guidance Document for Priority Cystic Fibrosis Lung Pathogens","authors":"E. Mahenthiralingam, R. Weiser, R. Floto, J. Davies, J. Fothergill","doi":"10.1007/s40588-022-00182-2","DOIUrl":"https://doi.org/10.1007/s40588-022-00182-2","url":null,"abstract":"","PeriodicalId":45506,"journal":{"name":"Current Clinical Microbiology Reports","volume":"9 1","pages":"33 - 45"},"PeriodicalIF":5.2,"publicationDate":"2022-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41773807","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-08-06DOI: 10.1007/s40588-022-00180-4
Chandni Sachdeva, K. Satyamoorthy, T. S. Murali
{"title":"Microbial Interplay in Skin and Chronic Wounds","authors":"Chandni Sachdeva, K. Satyamoorthy, T. S. Murali","doi":"10.1007/s40588-022-00180-4","DOIUrl":"https://doi.org/10.1007/s40588-022-00180-4","url":null,"abstract":"","PeriodicalId":45506,"journal":{"name":"Current Clinical Microbiology Reports","volume":"9 1","pages":"21 - 31"},"PeriodicalIF":5.2,"publicationDate":"2022-08-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44960008","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-03-10DOI: 10.1007/s40588-022-00176-0
Faith M. Anderson, Elizabeth J. Polvi, Amanda O. Veri, Teresa R. O’Meara
{"title":"Correction to: Germination of a Field: Women in Candida albicans Research","authors":"Faith M. Anderson, Elizabeth J. Polvi, Amanda O. Veri, Teresa R. O’Meara","doi":"10.1007/s40588-022-00176-0","DOIUrl":"https://doi.org/10.1007/s40588-022-00176-0","url":null,"abstract":"","PeriodicalId":45506,"journal":{"name":"Current Clinical Microbiology Reports","volume":"1 1","pages":"1"},"PeriodicalIF":5.2,"publicationDate":"2022-03-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47701917","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-03-01DOI: 10.1007/s40588-022-00177-z
M. Gorris, M. V. Van Dyke, A. Carey, Paris S. Hamm, Heather L. Mead, J. Uehling
{"title":"Correction to: A Review of Coccidioides Research, Outstanding Questions in the Field, and Contributions by Women Scientists","authors":"M. Gorris, M. V. Van Dyke, A. Carey, Paris S. Hamm, Heather L. Mead, J. Uehling","doi":"10.1007/s40588-022-00177-z","DOIUrl":"https://doi.org/10.1007/s40588-022-00177-z","url":null,"abstract":"","PeriodicalId":45506,"journal":{"name":"Current Clinical Microbiology Reports","volume":"9 1","pages":"10 - 10"},"PeriodicalIF":5.2,"publicationDate":"2022-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47273031","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-01-01Epub Date: 2022-09-27DOI: 10.1007/s40588-022-00181-3
Antonia Langfeldt, Jeremy A W Gold, Tom Chiller
Purpose of review: For this review, we use a One Health approach to examine two globally emerging public health threats related to antifungal drug resistance: triazole-resistant Aspergillus fumigatus infections, which can cause a life-threatening illness in immunocompromised hosts, and antifungal-resistant dermatophytosis, which is an aggressive skin infection caused by dermatophyte molds. We describe the state of current scientific knowledge and outline necessary public health actions to address each issue.
Recent findings: Recent evidence has identified the agricultural use of triazole fungicides as an important driver of triazole-resistant A. fumigatus infections. Antifungal-resistant dermatophyte infections are likely driven by the inappropriate use of antifungal drugs and antibacterial and corticosteroid creams.
Summary: This review highlights the need for a One Health approach to address emerging antifungal resistant infections, emphasizing judicious antifungal use to preserve available treatments; strengthened laboratory capacity to identify antifungal resistance; and improved human, animal, and environmental surveillance to detect emerging resistance, monitor trends, and evaluate the effectiveness of efforts to decrease spread.
{"title":"Emerging Fungal Infections: from the Fields to the Clinic, Resistant <i>Aspergillus fumigatus</i> and Dermatophyte Species: a One Health Perspective on an Urgent Public Health Problem.","authors":"Antonia Langfeldt, Jeremy A W Gold, Tom Chiller","doi":"10.1007/s40588-022-00181-3","DOIUrl":"10.1007/s40588-022-00181-3","url":null,"abstract":"<p><strong>Purpose of review: </strong>For this review, we use a One Health approach to examine two globally emerging public health threats related to antifungal drug resistance: triazole-resistant <i>Aspergillus fumigatus</i> infections, which can cause a life-threatening illness in immunocompromised hosts, and antifungal-resistant dermatophytosis, which is an aggressive skin infection caused by dermatophyte molds. We describe the state of current scientific knowledge and outline necessary public health actions to address each issue.</p><p><strong>Recent findings: </strong>Recent evidence has identified the agricultural use of triazole fungicides as an important driver of triazole-resistant <i>A. fumigatus</i> infections. Antifungal-resistant dermatophyte infections are likely driven by the inappropriate use of antifungal drugs and antibacterial and corticosteroid creams.</p><p><strong>Summary: </strong>This review highlights the need for a One Health approach to address emerging antifungal resistant infections, emphasizing judicious antifungal use to preserve available treatments; strengthened laboratory capacity to identify antifungal resistance; and improved human, animal, and environmental surveillance to detect emerging resistance, monitor trends, and evaluate the effectiveness of efforts to decrease spread.</p>","PeriodicalId":45506,"journal":{"name":"Current Clinical Microbiology Reports","volume":"9 4","pages":"46-51"},"PeriodicalIF":3.1,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9512973/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10735856","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-01-01DOI: 10.1007/s40588-022-00183-1
Fredrickson B Wasswa, Kennedy Kassaza, Kirsten Nielsen, Joel Bazira
Purpose of review: The introduction of MinION whole-genome sequencing technology greatly increased and simplified complete genome sequencing in various fields of science across the globe. Sequences have been generated from complex organisms to microorganisms and are stored in genome databases that are readily accessible by researchers. Various new software for genome analysis, along with upgrades to older software packages, are being generated. New protocols are also being validated that enable WGS technology to be rapidly and increasingly used for sequencing in field settings.
Recent findings: MinION WGS technology has been implemented in developed countries due to its advantages: portability, real-time analysis, and lower cost compared to other sequencing technologies. While these same advantages are critical in developing countries, MinION WGS technology is still under-utilized in resource-limited settings.
Summary: In this review, we look at the applications, advantages, challenges, and opportunities of using MinION WGS in resource-limited settings.
{"title":"MinION Whole-Genome Sequencing in Resource-Limited Settings: Challenges and Opportunities.","authors":"Fredrickson B Wasswa, Kennedy Kassaza, Kirsten Nielsen, Joel Bazira","doi":"10.1007/s40588-022-00183-1","DOIUrl":"https://doi.org/10.1007/s40588-022-00183-1","url":null,"abstract":"<p><strong>Purpose of review: </strong>The introduction of MinION whole-genome sequencing technology greatly increased and simplified complete genome sequencing in various fields of science across the globe. Sequences have been generated from complex organisms to microorganisms and are stored in genome databases that are readily accessible by researchers. Various new software for genome analysis, along with upgrades to older software packages, are being generated. New protocols are also being validated that enable WGS technology to be rapidly and increasingly used for sequencing in field settings.</p><p><strong>Recent findings: </strong>MinION WGS technology has been implemented in developed countries due to its advantages: portability, real-time analysis, and lower cost compared to other sequencing technologies. While these same advantages are critical in developing countries, MinION WGS technology is still under-utilized in resource-limited settings.</p><p><strong>Summary: </strong>In this review, we look at the applications, advantages, challenges, and opportunities of using MinION WGS in resource-limited settings.</p>","PeriodicalId":45506,"journal":{"name":"Current Clinical Microbiology Reports","volume":"9 4","pages":"52-59"},"PeriodicalIF":5.2,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9669520/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9601454","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-01-01DOI: 10.1007/s40588-022-00184-0
Harnoor Singh Pruthi
Purpose of review: Severe-acute respiratory coronavirus 2 (SARS-CoV-2) has been driving the health care delivery system for over 2 years. With time, many issues related to co-infections in COVID-19 patients are constantly surfacing. There have been numerous reports about various fungal co-infections in patients with COVID-19. The extent of severity of fungal pathogens has been recognized as a substantial cause of morbidity and mortality in this population. Awareness, understanding, and a systematic approach to managing fungal co-infections in COVID-19 patients are important. No guidelines have enumerated the stepwise approach to managing the fungal infections co-occurring with COVID-19. This review is intended to present an overview of the fungal co-infections in COVID-19 patients and their stepwise screening and management.
Recent findings: The most common fungal infections that have been reported to co-exist with COVID-19 are Candidemia, Aspergillosis, and Mucormycosis. Prevalence of co-infections in COVID-19 patients has been reported to be much higher in hospitalized COVID-19 patients, especially those in intensive care units. While clear pathogenetic mechanisms have not been delineated, COVID-19 patients are at a high risk of invasive fungal infections.
Summary: As secondary fungal infections have been challenging to treat in COVID-19 patients, as they tend to affect the critically ill or immunocompromised patients, a delay in diagnosis and treatment may be fatal. Antifungal drugs should be initiated with caution after carefully assessing the immune status of the patients, drug interactions, and adverse effects. The crucial factors in successfully treating fungal infections in COVID-19 patients are optimal diagnostic approach, routine screening, and timely initiation of antifungal therapy.
{"title":"When to Initiate Antifungal Treatment in COVID-19 Patients with Secondary Fungal Co-infection.","authors":"Harnoor Singh Pruthi","doi":"10.1007/s40588-022-00184-0","DOIUrl":"https://doi.org/10.1007/s40588-022-00184-0","url":null,"abstract":"<p><strong>Purpose of review: </strong>Severe-acute respiratory coronavirus 2 (SARS-CoV-2) has been driving the health care delivery system for over 2 years. With time, many issues related to co-infections in COVID-19 patients are constantly surfacing. There have been numerous reports about various fungal co-infections in patients with COVID-19. The extent of severity of fungal pathogens has been recognized as a substantial cause of morbidity and mortality in this population. Awareness, understanding, and a systematic approach to managing fungal co-infections in COVID-19 patients are important. No guidelines have enumerated the stepwise approach to managing the fungal infections co-occurring with COVID-19. This review is intended to present an overview of the fungal co-infections in COVID-19 patients and their stepwise screening and management.</p><p><strong>Recent findings: </strong>The most common fungal infections that have been reported to co-exist with COVID-19 are Candidemia, Aspergillosis, and Mucormycosis. Prevalence of co-infections in COVID-19 patients has been reported to be much higher in hospitalized COVID-19 patients, especially those in intensive care units. While clear pathogenetic mechanisms have not been delineated, COVID-19 patients are at a high risk of invasive fungal infections.</p><p><strong>Summary: </strong>As secondary fungal infections have been challenging to treat in COVID-19 patients, as they tend to affect the critically ill or immunocompromised patients, a delay in diagnosis and treatment may be fatal. Antifungal drugs should be initiated with caution after carefully assessing the immune status of the patients, drug interactions, and adverse effects. The crucial factors in successfully treating fungal infections in COVID-19 patients are optimal diagnostic approach, routine screening, and timely initiation of antifungal therapy.</p>","PeriodicalId":45506,"journal":{"name":"Current Clinical Microbiology Reports","volume":"9 4","pages":"60-68"},"PeriodicalIF":5.2,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9630809/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10368281","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-01-01Epub Date: 2022-04-09DOI: 10.1007/s40588-022-00179-x
Juan Carlos Cataño-Correa, Jaiberth Antonio Cardona-Arias, Jessica Paola Porras-Mancilla, Marcela Tabares-García
Purpose of review: This study compares the survival and clinical profile of hospitalized adults with COVID-19 in two clinics in the city of Medellín, Colombia, with a prospective study with 198 patients in clinic A and 201 in clinic B. Comparisons were made with chi-square and Mann-Whitney U, factors associated with survival were identified with a Cox regression.
Recent findings: The proportion of deaths was 7.1% in clinic A with a mean survival of 51.9 days (95% CI = 45-59); in clinic B 13.9% of patients died with mean survival of 37.8 days (95% CI = 32-43). The most prevalent comorbidities were hypertension (41.6%), diabetes (23.8%), obesity (15.0%), hypothyroidism (13.0%), dyslipidemia (11.0%), and chronic lung disease (10.8%) with similar proportions in both clinics. There were also differences by the clinic in the most prevalent complications: bacterial pneumonia (18.8%), acute renal failure (14.3%), and encephalopathy (9.5%). There were no differences in the days of hospitalization, mechanical ventilation (clinic A 23.7% and clinic B 29.4%) and admission to the ICU (25.3% in A and 32.3% in B).
Summary: We evidence the heterogeneity of the survival and the clinical profile of the patients who are cared for by two institutions of the same city. These findings demonstrate the need to conduct unique studies for each institution, which poses a significant challenge for hospital epidemiology programs due to the impossibility of extrapolating evidence from other healthcare institutions and the need to implement personalized medicine programs given the clinical diversity of patients hospitalized for COVID-19.
综述目的:本研究比较了哥伦比亚麦德林市两家诊所的COVID-19住院成人患者的存活率和临床概况,其中A诊所收治了198名患者,B诊所收治了201名患者,并进行了前瞻性研究:A诊所的死亡比例为7.1%,平均生存期为51.9天(95% CI = 45-59);B诊所的死亡比例为13.9%,平均生存期为37.8天(95% CI = 32-43)。最常见的合并症是高血压(41.6%)、糖尿病(23.8%)、肥胖(15.0%)、甲状腺功能减退(13.0%)、血脂异常(11.0%)和慢性肺病(10.8%),两家诊所的比例相似。各诊所在最常见并发症方面也存在差异:细菌性肺炎(18.8%)、急性肾功能衰竭(14.3%)和脑病(9.5%)。住院天数、机械通气(A 诊所为 23.7%,B 诊所为 29.4%)和入住重症监护室(A 诊所为 25.3%,B 诊所为 32.3%)方面没有差异。这些研究结果表明,有必要对每个机构进行独特的研究,这对医院流行病学项目提出了重大挑战,因为无法从其他医疗机构推断证据,而且鉴于 COVID-19 住院患者的临床多样性,有必要实施个性化医疗项目。
{"title":"Comparison of Survival and Clinical Profile of Adults with COVID-19 Hospitalized in Two Clinics in Medellín, Colombia.","authors":"Juan Carlos Cataño-Correa, Jaiberth Antonio Cardona-Arias, Jessica Paola Porras-Mancilla, Marcela Tabares-García","doi":"10.1007/s40588-022-00179-x","DOIUrl":"10.1007/s40588-022-00179-x","url":null,"abstract":"<p><strong>Purpose of review: </strong>This study compares the survival and clinical profile of hospitalized adults with COVID-19 in two clinics in the city of Medellín, Colombia, with a prospective study with 198 patients in clinic A and 201 in clinic B. Comparisons were made with chi-square and Mann-Whitney <i>U</i>, factors associated with survival were identified with a Cox regression.</p><p><strong>Recent findings: </strong>The proportion of deaths was 7.1% in clinic A with a mean survival of 51.9 days (95% CI = 45-59); in clinic B 13.9% of patients died with mean survival of 37.8 days (95% CI = 32-43). The most prevalent comorbidities were hypertension (41.6%), diabetes (23.8%), obesity (15.0%), hypothyroidism (13.0%), dyslipidemia (11.0%), and chronic lung disease (10.8%) with similar proportions in both clinics. There were also differences by the clinic in the most prevalent complications: bacterial pneumonia (18.8%), acute renal failure (14.3%), and encephalopathy (9.5%). There were no differences in the days of hospitalization, mechanical ventilation (clinic A 23.7% and clinic B 29.4%) and admission to the ICU (25.3% in A and 32.3% in B).</p><p><strong>Summary: </strong>We evidence the heterogeneity of the survival and the clinical profile of the patients who are cared for by two institutions of the same city. These findings demonstrate the need to conduct unique studies for each institution, which poses a significant challenge for hospital epidemiology programs due to the impossibility of extrapolating evidence from other healthcare institutions and the need to implement personalized medicine programs given the clinical diversity of patients hospitalized for COVID-19.</p>","PeriodicalId":45506,"journal":{"name":"Current Clinical Microbiology Reports","volume":"9 1","pages":"11-19"},"PeriodicalIF":3.1,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8993667/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46756479","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-12-01Epub Date: 2021-04-24DOI: 10.1007/s40588-021-00168-6
Lauren Butler, Keenan A Walker
Purpose of review: Herein, we provide a critical review of the clinical and translational research examining the relationship between viral and bacterial pathogens and Alzheimer's disease. In addition, we provide an overview of the biological pathways through which chronic infection may contribute to Alzheimer's disease.
Recent findings: Dementia due to Alzheimer's disease is a leading cause of disability among older adults in developed countries, yet knowledge of the causative factors that promote Alzheimer's disease pathogenesis remains incomplete. Over the past several decades, numerous studies have demonstrated an association of chronic viral and bacterial infection with Alzheimer's disease. Implicated infectious agents include numerous herpesviruses (HSV-1, HHV-6, HHV-7) and various gastric, enteric, and oral bacterial species, as well as Chlamydia pneumonia and multiple spirochetes.
Summary: Evidence supports the association between multiple pathogens and Alzheimer's disease risk. Whether these pathogens play a causal role in Alzheimer's pathophysiology remains an open question. We propose that the host immune response to active or latent infection in the periphery or in the brain triggers or accelerates the Alzheimer's disease processes, including the accumulation of amyloid-ß and pathogenic tau, and neuroinflammation. While recent research suggests that such theories are plausible, additional longitudinal studies linking microorganisms to Aß and phospho-tau development, neuroinflammation, and clinically defined Alzheimer's dementia are needed.
综述的目的:在此,我们对研究病毒和细菌病原体与阿尔茨海默病之间关系的临床和转化研究进行了重要综述。此外,我们还概述了慢性感染可能导致阿尔茨海默病的生物学途径:阿尔茨海默病导致的痴呆是发达国家老年人致残的主要原因,但人们对促进阿尔茨海默病发病机制的致病因素的了解仍不全面。在过去的几十年中,大量研究表明慢性病毒和细菌感染与阿尔茨海默病有关。涉及的感染病原体包括多种疱疹病毒(HSV-1、HHV-6、HHV-7)和多种胃肠道和口腔细菌,以及肺炎衣原体和多种螺旋体。这些病原体是否在阿尔茨海默病的病理生理学中起着因果作用仍是一个未决问题。我们提出,宿主对外周或大脑中活跃或潜伏感染的免疫反应触发或加速了阿尔茨海默病的发病过程,包括淀粉样蛋白-ß和致病性 tau 的积累以及神经炎症。虽然最近的研究表明这种理论是可信的,但还需要进行更多的纵向研究,将微生物与 Aß 和磷酸化 tau 的发展、神经炎症和临床定义的阿尔茨海默氏症痴呆症联系起来。
{"title":"The Role of Chronic Infection in Alzheimer's Disease: Instigators, Co-conspirators, or Bystanders?","authors":"Lauren Butler, Keenan A Walker","doi":"10.1007/s40588-021-00168-6","DOIUrl":"10.1007/s40588-021-00168-6","url":null,"abstract":"<p><strong>Purpose of review: </strong>Herein, we provide a critical review of the clinical and translational research examining the relationship between viral and bacterial pathogens and Alzheimer's disease. In addition, we provide an overview of the biological pathways through which chronic infection may contribute to Alzheimer's disease.</p><p><strong>Recent findings: </strong>Dementia due to Alzheimer's disease is a leading cause of disability among older adults in developed countries, yet knowledge of the causative factors that promote Alzheimer's disease pathogenesis remains incomplete. Over the past several decades, numerous studies have demonstrated an association of chronic viral and bacterial infection with Alzheimer's disease. Implicated infectious agents include numerous herpesviruses (HSV-1, HHV-6, HHV-7) and various gastric, enteric, and oral bacterial species, as well as <i>Chlamydia pneumonia</i> and multiple spirochetes.</p><p><strong>Summary: </strong>Evidence supports the association between multiple pathogens and Alzheimer's disease risk. Whether these pathogens play a causal role in Alzheimer's pathophysiology remains an open question. We propose that the host immune response to active or latent infection in the periphery or in the brain triggers or accelerates the Alzheimer's disease processes, including the accumulation of amyloid-ß and pathogenic tau, and neuroinflammation. While recent research suggests that such theories are plausible, additional longitudinal studies linking microorganisms to Aß and phospho-tau development, neuroinflammation, and clinically defined Alzheimer's dementia are needed.</p>","PeriodicalId":45506,"journal":{"name":"Current Clinical Microbiology Reports","volume":"8 4","pages":"199-212"},"PeriodicalIF":3.1,"publicationDate":"2021-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8849576/pdf/nihms-1716713.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39940433","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-09-12DOI: 10.1007/s40588-021-00175-7
S. Johler, C. Guldimann
{"title":"An Introduction to Current Trends in Meat Microbiology and Hygiene","authors":"S. Johler, C. Guldimann","doi":"10.1007/s40588-021-00175-7","DOIUrl":"https://doi.org/10.1007/s40588-021-00175-7","url":null,"abstract":"","PeriodicalId":45506,"journal":{"name":"Current Clinical Microbiology Reports","volume":"1 1","pages":""},"PeriodicalIF":5.2,"publicationDate":"2021-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44749036","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}